RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
Agios Pharmaceuticals, Inc. +0.53% Post
Agios Pharmaceuticals, Inc. AGIO | 34.37 34.37 | +0.53% 0.00% Post |
RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:
AGIO) with a Outperform and maintains $55 price target.
